At the Neuropsychoimaging of Addiction and Related Conditions (NARC) Research Program at Mount Sinai, our research team explores the human brain functions as they relate to drug addiction. Our research helps us learn how to improve the lives of people with addictions.
Our current studies include:
Mindfulness-Oriented Recovery Enhancement for Treatment of Heroin Use Disorder
Overdose deaths related to opioid use (including heroin) continue to soar in the United States, with very little known about the neurobiology of heroin addiction or its treatment. According to seminal research in our lab, drug-biased salience attribution, accompanied by impairments in inhibitory control, characterizes the core symptomology of drug addiction. A promising addiction intervention that targets these deficits is the Mindfulness-Oriented Recovery Enhancement (MORE) program, an eight-week behavioral therapy that aims to reduce the excessive salience ascribed to drug cues, while enhancing natural reward responsiveness. In this randomized clinical trial, we assess neural function (e.g., reactivity to drug cues, inhibitory control) and structure in inpatient, medication-assisted individuals with heroin use disorder, before and after randomization into MORE or standard group therapy. We also focus on fluctuations in important clinical endpoints via naturalistic and longitudinal examinations of motivation, craving, and drug-use behaviors. The results from these investigations will contribute to our understanding of the brain bases of heroin addiction recovery and offer translational insights for effective therapeutic interventions.
This work is funded by NCCIH R01 AT010627. Clinical trial ID: NCT04112186.
Relevant publications:
- Prefrontal-habenular microstructural impairments in human cocaine and heroin addiction
- Common and distinct fronto-striatal volumetric changes in heroin and cocaine use disorders
- Whole-brain white matter abnormalities in human cocaine and heroin use disorders: association with craving, recency, and cumulative use
- The Neural Signature of Impaired Inhibitory Control in Individuals with Heroin Use Disorder
Sex Differences in the Neural Correlates Underlying Cocaine and Heroin Addiction
The Sex Differences project seeks to investigate the neurobiological underpinnings of sex differences in substance use disorder (SUD), with a specific focus on cocaine addiction in women. Despite evidence demonstrating that women are at a greater risk of experiencing more severe addiction-related symptoms and drug-use patterns, as well as relapse, neuroimaging studies have largely overlooked women participants. The project aims to address this research gap and examine the effect of the menstrual cycle (i.e., follicular versus luteal phase) on the functions of reward/salience attribution and inhibitory control under the impaired response inhibition and salience attribution (iRISA) model. By recruiting equal numbers of women and men, including individuals with SUD and healthy controls, the project aims to elucidate the mechanisms underlying SUD in women and develop gender-tailored interventions to reduce craving and improve treatment outcomes. Through this research, the project hopes to make a significant contribution to addressing the unique public health concern of the rapid increase in drug use among women in the United States.
This work is funded by NIDA R01 DA048301-01A1.
Relevant publications:
- Overdose mortality rates for opioids or stimulants are higher in males than females, controlling for rates of drug misuse: State-level data
- Common and gender-specific associations with cocaine use on gray matter volume: Data from the ENIGMA addiction working group
- Converging effects of cocaine addiction and sex on neural responses to monetary rewards
Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder
Transcranial direct current stimulation (tDCS) is a brain stimulation technique that uses weak constant currents and produces lasting functional changes in the central nervous system. It is a noninvasive, low-cost, well tolerated, and importantly in the current context, portable device that can be used outside of clinical settings. The goal of this clinical trial is to establish the efficacy of repeated tDCS over the dorsolateral prefrontal cortex in reducing cravings in individuals with cocaine use disorder living in inpatient drug-rehabilitation facilities, where self-administration using home-tDCS devices could improve treatment reach and compliance. Individuals with cocaine use disorder receive 15 sessions of tDCS over five weeks and multiple EEG recordings and behavioral assessments to measure changes in objective and subjective drug cravings as well as general drug-related clinical variables, cognitive functioning, and sleep/wake cycle variability.
This work is funded by NIDA 271201800035C-0-0-1.
Relevant publications:
Imaging Atherosclerosis in Drug Addiction
This multidisciplinary project is led by Principal Investigator Nelly Alia-Klein, PhD. People with cocaine use disorders (CUD) often have years of exposure to the drug, reaching into middle adulthood and later. It is known that people with SUD are at increased risk of strokes, often triggered by buildup of atherosclerotic plaque in coronary arteries. The neurovascular effects of chronic cocaine can also result in cognitive dysfunction. The goal of this study is to determine if coronary artery disease, as examined by ultrasound and clinical methods, will correlate with cognitive processing and brain function as examined with functional MRI. Results from this multidisciplinary study could identify major risk factors for the decline in quality of life and cognitive function that could be observed in people with chronic cocaine exposure.
This work is funded by NIDA R01 DA049547-01.
Relevant publications:
- Imaging plaque inflammation in asymptomatic cocaine addicted individuals with simultaneous positron emission tomography/magnetic resonance imaging
- Vascular disease in cocaine addiction
Targeting Neural, Behavioral, and Pharmacological Mechanisms of Drug Memories with Methylphenidate
Salient memories of the drug use contribute to craving and relapse even after long periods of abstinence. Traditional cue-exposure therapies aimed at extinguishing these memories have not been effective at preventing relapse, warranting the development of alternative strategies. The goal of this project is to identify a pharmacologically enhanced learning and memory approach that aims to decrease craving and relapse in drug addiction. Here, we target the mechanisms underlying memory reconsolidation, a time-dependent process in which specific consolidated memories may become amenable to change (e.g., memory disruption). We will enhance this behavioral approach pharmacologically in individuals with cocaine use disorder (iCUD), using methylphenidate (MPH, a dopamine agonist) as a cognitive enhancer to promote learning-induced neural plasticity in iCUD. In a placebo-controlled design, we will psychophysiologically measure memory modification via functional magnetic resonance imaging and skin conductance responses following MPH, with a follow-up the following day, permitting the assessment of drug-cue memory disruption and effects on craving. Results from this project could ultimately be used to develop effective cue-exposure therapies to reduce cue-induced craving and relapse.
This work is funded by NIDA 1R21DA054281-01.
Relevant publications:
- Neural mechanisms of extinguishing drug and pleasant cue associations in human addiction: role of the VMPFC
- Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task
- Effects of Methylphenidate on Resting-State Functional Connectivity of the Mesocorticolimbic Dopamine Pathways in Cocaine Addiction
Diagnostic and prognostic biomarkers for subtypes of addictions-related circuit dysfunction
In collaboration with Conor Liston, MD, PhD, of Weil Cornell, we are using a recently developed and validated approach to discovering and diagnosing subtypes of SUD using functional magnetic resonance imaging (fMRI) measures of functional connectivity. In a secondary data analysis, we are leveraging multiple deeply characterized and large-scale neuroimaging datasets. Our central hypothesis is that individual differences in mechanisms underlying iRISA are mediated by distinct forms of dysfunctional connectivity in addiction-related circuits, which in turn interact and give rise to distinct neurophysiological addiction subtypes. Here we are using statistical clustering and machine-learning methods to delineate these subtypes and optimize classifiers (fMRI biomarkers) for diagnosing them in individual patients, focusing initially on cocaine addiction. Then, we validate these subtype-specific biomarkers by first replicating them in a new dataset and then evaluating their longitudinal stability and predictive utility. Finally, we will test whether subtype-specific circuit mechanisms generalize to mediate iRISA functions in other forms of addiction, and define their interactions with distinct mechanisms mediating anhedonia and anxious arousal in patients with comorbid depression and anxiety.
This work is funded by NIDA R01 DA047851-01A1.